Lin Li1, Susan Jick2, Stefanie Breitenstein3, Alexander Michel4. 1. Boston Collaborative Drug Surveillance Program, Boston University School of Public Health, Lexington, MA linli07@bu.edu. 2. Boston Collaborative Drug Surveillance Program, Boston University School of Public Health, Lexington, MA. 3. Global Clinical Development, Bayer Pharma AG, Wuppertal, Germany. 4. Global Epidemiology, Bayer Pharma AG, Berlin, Germany.
Abstract
OBJECTIVE: To estimate the prevalence of diabetes and diabetic nephropathy in a large population of U.S. commercially insured patients aged <18 years from 2002 to 2013. RESEARCH DESIGN AND METHODS: Using the U.S. MarketScan Commercial Claims and Encounters Database, we identified 96,171 pediatric patients with diabetes and 3,161 pediatric patients with diabetic nephropathy during 2002-2013. We estimated prevalence of pediatric diabetes overall, by diabetes type, age, and sex, and prevalence of pediatric diabetic nephropathy overall, by age, sex, and diabetes type. RESULTS: The annual prevalence of diabetes in the whole pediatric population increased from 1.86 to 2.82 per 1,000 during 2002-2013: 1.48 to 2.32 per 1,000 for type 1 diabetes and 0.38 to 0.67 per 1,000 for type 2 diabetes in 2002-2006 and then 0.56 to 0.49 per 1,000 thereafter. The annual prevalence of diabetic nephropathy in pediatric patients with diabetes increased from 1.16 to 3.44% for all cases and 0.83 to 2.32% for probable cases only in 2002-2013. Prevalence of diabetes and diabetic nephropathy was highest in patients aged 12 to <18 years. While prevalence of type 1 diabetes was higher in male than in female youth, prevalence of type 2 diabetes and diabetic nephropathy was higher in female than in male youth. There was no difference in prevalence of diabetic nephropathy by diabetes type. CONCLUSIONS: The prevalence of diabetes and diabetic nephropathy increased in the U.S. MarketScan commercially insured pediatric population from 2002 to 2013. The prevalence of diabetes and diabetic nephropathy markedly increased starting at age 12 years.
OBJECTIVE: To estimate the prevalence of diabetes and diabetic nephropathy in a large population of U.S. commercially insured patients aged <18 years from 2002 to 2013. RESEARCH DESIGN AND METHODS: Using the U.S. MarketScan Commercial Claims and Encounters Database, we identified 96,171 pediatric patients with diabetes and 3,161 pediatric patients with diabetic nephropathy during 2002-2013. We estimated prevalence of pediatric diabetes overall, by diabetes type, age, and sex, and prevalence of pediatric diabetic nephropathy overall, by age, sex, and diabetes type. RESULTS: The annual prevalence of diabetes in the whole pediatric population increased from 1.86 to 2.82 per 1,000 during 2002-2013: 1.48 to 2.32 per 1,000 for type 1 diabetes and 0.38 to 0.67 per 1,000 for type 2 diabetes in 2002-2006 and then 0.56 to 0.49 per 1,000 thereafter. The annual prevalence of diabetic nephropathy in pediatric patients with diabetes increased from 1.16 to 3.44% for all cases and 0.83 to 2.32% for probable cases only in 2002-2013. Prevalence of diabetes and diabetic nephropathy was highest in patients aged 12 to <18 years. While prevalence of type 1 diabetes was higher in male than in female youth, prevalence of type 2 diabetes and diabetic nephropathy was higher in female than in male youth. There was no difference in prevalence of diabetic nephropathy by diabetes type. CONCLUSIONS: The prevalence of diabetes and diabetic nephropathy increased in the U.S. MarketScan commercially insured pediatric population from 2002 to 2013. The prevalence of diabetes and diabetic nephropathy markedly increased starting at age 12 years.
Authors: Zachary E West; Sharon M Castellino; Caitlin Monroe; Amanda S Thomas; Courtney McCracken; Tamara P Miller Journal: Leuk Lymphoma Date: 2020-12-01
Authors: Jean M Lawrence; Jasmin Divers; Scott Isom; Sharon Saydah; Giuseppina Imperatore; Catherine Pihoker; Santica M Marcovina; Elizabeth J Mayer-Davis; Richard F Hamman; Lawrence Dolan; Dana Dabelea; David J Pettitt; Angela D Liese Journal: JAMA Date: 2021-08-24 Impact factor: 157.335
Authors: Dianna J Magliano; Julian W Sacre; Jessica L Harding; Edward W Gregg; Paul Z Zimmet; Jonathan E Shaw Journal: Nat Rev Endocrinol Date: 2020-03-20 Impact factor: 43.330
Authors: Pirjo Hakkarainen; Reijo Sund; Martti Arffman; Sari Koski; Vilma Hänninen; Leena Moilanen; Kimmo Räsänen Journal: BMC Public Health Date: 2017-10-12 Impact factor: 3.295